Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

Silvia Antolín,1 Benigno Acea,2 Luis Albaina,2 Ángel Concha,3 Paz Santiago,3 Tomás García-Caballero,4 Joaquín J Mosquera,5 José Ramón Varela,5 Rafaela Soler,5 Lourdes Calvo1 1Medical Oncology Department, Breast Unit, A Coru...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antolín S, Acea B, Albaina L, Concha Á, Santiago P, García-Caballero T, Mosquera JJ, Varela JR, Soler R, Calvo L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Neoadjuvant therapy HER2-positive breast cancer pathologic complete response cardiotoxicity survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/baccee9a46d042eca38ea148ccbfb013
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

Ejemplares similares